<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Strategic Partnership on FinanClub</title>
    <link>https://finan.club/tags/strategic-partnership/</link>
    <description>Recent content in Strategic Partnership on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 14 Dec 2023 09:03:33 +0000</lastBuildDate><atom:link href="https://finan.club/tags/strategic-partnership/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>ROIV</title>
      <link>https://finan.club/us/roiv/</link>
      <pubDate>Thu, 14 Dec 2023 09:03:33 +0000</pubDate>
      
      <guid>https://finan.club/us/roiv/</guid>
      <description>score:-74
Chances: Roivant Sciences Ltd. has shown promising results in its Phase 1 studies for IMVT-1402, with similar effects to its existing product, Batoclimab. The sale of Telavant to Roche for $7.1B upfront indicates a significant positive financial development for Roivant. The addition of Dr.</description>
    </item>
    
  </channel>
</rss>
